Robert Laing

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi et al. · The Lancet · 2021 · 564 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +6

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 521 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +11

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Nicholas D. James, Melissa Spears, Noel W. Clarke et al. · European Urology · 2014 · 436 citations · Full text

Medicine, Biostatistics, Oncology +17

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2022 · 384 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14